Obermatt
See Similar Stocks →

Abbott India

NSI:ABBOTINDIA · INE358A01014
PharmaceuticalsMedium

360

42
Medium confidence — indicative
EV / EBIT17
Price / Owner Earnings37
Owner Earnings Yield49
Dividend Yield1
Price/Sales25
EV / Gross Profit9
Price/Book16
Return on Capital97
Cash Return on Capital94
Return on Equity93
EBIT Margin78
Gross Profitability76
Cash Conversion20
Owner Earnings Margin82
Sales growth22
Profit Growth74
Long-Term EPS Growth49
Reinvestment71
Price momentum30
Debt load70
Refinancing46
Debt Payback100
Liquidity87
Analyst ratings26
Opinion Changes92
Price Target Upside60
Market mood81
Value Creation13/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Abbott India clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Based on 3/5 components.

Profile

CountryUSA
IndustryPharmaceuticals
SizeMedium
TypePublic Company
ExchangeBSE
Founded1944
Employees927
Websiteabbott.co.in
ISININE358A01014
Last UpdateApr 2, 2026
Index & Theme
Pain ManagementRespiratoryVaccinesNeurologyWomen's HealthCentral Nervous SystemGastroenterologyHealth CareMedical DevicePharmaceuticalProduct Design

Description

Abbott India Limited (Abbott India) is a healthcare-focused organization committed to improving the quality of life for people through innovative products and services. With a workforce of 3,597 employees, Abbott India has established a strong footho…

Analysis

Quality compounder

Abbott India Limited is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.

The price is expensive. You pay 32.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 13% yearly growth; analysts expect 12%. The price, in other words, assumes less than the experts do.

The trajectory is tepid and the balance sheet is sturdy. The company scores 13/20 on our value-creation score: creating some value. Analyst sentiment is cautious.

What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
42
2023202420252026

All-time high

87

Jan 2025

All-time low

42

Jun 2026

Average rank

60

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
25
7
20
22
Price/Earnings
8
23
18
22
Price/Book
16
10
12
10
Dividend Yield
1
63
63
40
Value (overall)
1
19
19
13

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Abbott India with its peers
Prestige Consumer Healthcare
NYQ:PBH
60
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Journey Medical Corporation
NAQ:DERM
73
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
BIOAGE Labs
NSQ:BIOA
23
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Bausch Health Companies
TOR:BHC
21
CountryCanada
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Johnson & Johnson
NYQ:JNJ
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Merck (USA)
NYQ:MRK
35
CountryUSA
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →